产品
编 号：F483747
分子式：C30H31F3N8O
分子量：576.62
分子式：C30H31F3N8O
分子量：576.62
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 859212-16-1
产品详情
生物活性：
Bafetinib is an orally active Lyn/Bcr-Abl tyrosine kinase inhibitor. Bafetinib enhances the activity of several pro-apoptotic Bcl-2 homology (BH) 3-pure proteins (Bim, Bad, Bmf, and Bik) through intrinsic apoptotic pathways regulated by the Bcl-2 family, and induces apoptosis of Ph+ leukemia cells. Bafetinib has antitumor activity.
体内研究：
Bafetinib (30 mg/kg/day, 口服, 连续 10 天) 可抑制小鼠肺癌中 PD-L1 的表达。Bafetinib (10 mg/kg, 灌胃, 单剂量) 通过抑制 PAR2 诱导的 TRPV4 通道激活减轻小鼠疼痛。Animal Model:Murine inflammatory pain model
Dosage:10 mg/kg
Administration: i.g.
Result: Inhibited PAR2-induced mechanical hyperalgesia.
体外研究：
Bafetinib (0.625, 1.25, 2.5 μM,24 h) 通过 c-Myc 抑制肺癌细胞 H292 中 PD-L1的转录。
Bafetinib is an orally active Lyn/Bcr-Abl tyrosine kinase inhibitor. Bafetinib enhances the activity of several pro-apoptotic Bcl-2 homology (BH) 3-pure proteins (Bim, Bad, Bmf, and Bik) through intrinsic apoptotic pathways regulated by the Bcl-2 family, and induces apoptosis of Ph+ leukemia cells. Bafetinib has antitumor activity.
体内研究：
Bafetinib (30 mg/kg/day, 口服, 连续 10 天) 可抑制小鼠肺癌中 PD-L1 的表达。Bafetinib (10 mg/kg, 灌胃, 单剂量) 通过抑制 PAR2 诱导的 TRPV4 通道激活减轻小鼠疼痛。Animal Model:Murine inflammatory pain model
Dosage:10 mg/kg
Administration: i.g.
Result: Inhibited PAR2-induced mechanical hyperalgesia.
体外研究：
Bafetinib (0.625, 1.25, 2.5 μM,24 h) 通过 c-Myc 抑制肺癌细胞 H292 中 PD-L1的转录。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备